In a groundbreaking new publication in Genomic Psychiatry, researchers at Virginia Commonwealth University and Lund University have unveiled a pivotal advancement in our understanding of the genetic architecture underpinning psychiatric and substance use disorders. Under the leadership of Dr. Kenneth S. Kendler, the study embarked on an ambitious inquiry involving over two million individuals born in Sweden from 1950 to 1995, harnessing national registry data to explore genetic specificity — a concept that quantifies the extent to which inherited risks are unique to specific psychiatric conditions versus shared among various disorders.
Psychiatry has long grappled with the question of whether mental illnesses possess distinct hereditary signatures or represent diffuse genetic liabilities broadly predisposing individuals to a spectrum of psychiatric conditions. The debate dates back to the 19th century when early family studies ignited fierce contention over the nature of hereditary risk transmission. While modern techniques such as twin studies, molecular genetics, and polygenic risk scoring have demonstrated notable overlap in genetic risk factors among disorders like schizophrenia, bipolar disorder, depression, and substance use, the question of quantifying this overlap numerically has remained elusive — until now.
Dr. Kendler’s team devised an incisive methodological framework to tackle this challenge by focusing on nine diagnostically diverse psychiatric and substance use disorders: schizophrenia, bipolar disorder, alcohol use disorder, ADHD, autism spectrum disorder, PTSD, major depression, anxiety disorder, and drug use disorder. They computed family genetic risk scores (FGRS) from detailed morbidity patterns observed across relatives spanning five degrees of kinship. Importantly, analyses accounted for environmental confounders such as shared household effects. Through linear regression, the researchers isolated what fraction of the overall genetic signal in each diagnostic group was attributable specifically to that diagnosis, thereby assigning a precise “genetic specificity” value to each disorder.
The scope of this population-based study is unprecedented. Sample sizes ranged from tens of thousands for rarer diagnoses like schizophrenia (approximately 18,348 cases) to hundreds of thousands for more common disorders such as depression (674,955 cases). The encompassing Swedish registries provided a comprehensive dataset with robust diagnostic validity, enabling what may be the most definitive quantification of genetic specificity to date.
The results reveal a striking hierarchy that challenges existing psychiatric nosology. Schizophrenia topped the specificity scale with 73.1%, indicating that nearly three-quarters of the genetic liability in diagnosed individuals is unique to schizophrenia itself. Bipolar disorder followed with a moderate 54.8%, and alcohol use disorder registered similarly at 54.1%. A mid-level specificity cluster comprising ADHD, autism spectrum disorder, and PTSD hovered just below 50%, despite their distinct clinical presentations.
At the lower end of the spectrum, major depression, anxiety disorder, and especially drug use disorder exhibited markedly reduced genetic specificity, with drug use disorder’s specificity at a mere 29.5%. This suggests that a large proportion of genetic risk in drug use disorder is not disorder-specific but rather overlaps extensively with risks for schizophrenia, mood disorders, ADHD, and others. Such revelations bear profound implications, implying that some disorders may represent more genetically “pure” entities whereas others are downstream manifestations of broader, shared genetic vulnerabilities.
Beyond these static values, perhaps the most transformative discovery concerns the dynamism of genetic specificity itself. The research elegantly demonstrates that specificity fluctuates according to clinical parameters well-known to psychiatrists: age at onset, recurrence frequency, and treatment environment. Bipolar disorder exemplified this plasticity; early-onset cases exhibited significantly higher genetic specificity compared to late-onset cases, and patients with recurrent episodes showed elevated specificity compared to those with isolated episodes. Moreover, bipolar patients hospitalized for treatment had markedly higher specificity than those managed solely in primary care, with differences exceeding 30 percentage points.
Interestingly, PTSD displayed an inverse relationship, with later onset and outpatient care correlating with increased specificity. Across all conditions examined, greater recurrence uniformly predicted higher genetic specificity, underscoring that repeated episodes may serve as a clinical marker of genetically concentrated liability rather than generalized psychiatric vulnerability.
Delving deeper into clinical nuances, the study revealed contrasting genetic specificity patterns between depression and bipolar disorder relative to treatment settings. Hospitalized bipolar cases, likely admitted due to classic manic episodes, showed high disorder-specific genetic liability. Conversely, hospitalized depression cases manifested lower specificity, likely attributable to severe behavioral complications—such as suicidal ideation and substance misuse—that incorporate externalizing genetic influences. This dichotomy poses critical questions for research design: should depression genetic studies preferentially recruit from primary care to capture cleaner mood-related signals, while bipolar studies focus on inpatient samples?
Robust sensitivity analyses further bolster confidence in these findings. Adjustments for comorbid diagnoses minimally shifted specificity estimates, even after excluding cases with overlapping bipolar and depressive diagnoses. Sex-based analyses showed comparable specificity levels across genders for most disorders, except for alcohol and drug use disorders where males demonstrated significantly higher specificity — a difference the authors speculate might reflect socio-environmental influences attenuating genetic signals differently between men and women.
The team also performed leave-one-out analyses to examine interdependencies among disorders, uncovering expected genetic overlaps between highly correlated disorder pairs like depression-anxiety and alcohol-drug use disorders. These patterns confirm that specificity estimates inherently depend on the constellation of disorders considered, aligning with prior genetic epidemiology literature.
Compellingly, these findings dovetail with independent molecular genetic research. A recent 2026 Nature study led by Grotzinger identified a general psychopathology “P-factor” encompassing shared genetic variance across numerous psychiatric conditions, grouping disorders with low genetic specificity (depression, anxiety, PTSD) under internalizing subfactors strongly linked to this global factor. In contrast, schizophrenia and bipolar disorder formed a more distinct factor with relatively modest ties to the P-factor, mirroring the specificity gradients observed by Kendler and colleagues. The convergence of results drawn from divergent datasets and methodologies significantly strengthens the validity of genetic specificity as a meaningful construct.
Nevertheless, several limitations merit acknowledgment. Reliance on registry diagnoses, though extensive and validated, lacks the granularity of structured clinical interviews. Family genetic risk scores differ conceptually from polygenic risk scores derived from genomic sequencing, though prior work suggests functional concordance. The largely Scandinavian cohort raises questions about generalizability to other populations with different genetic backgrounds or health care systems. Moreover, the ever-present influence of comorbidity inherently shapes specificity, as disorders with high shared comorbidity and modest heritability (like depression) naturally yield lower specificity compared to highly heritable, less comorbid illnesses (schizophrenia).
Looking ahead, the implications for psychiatric genetics and clinical practice are extensive. Researchers can refine participant selection to either amplify or attenuate genetic specificity, depending on study aims. Clinicians may harness observable clinical features—age at onset, recurrence, and treatment setting—as proxies to infer underlying genetic architecture, potentially guiding prognosis and personalized interventions. Perhaps most importantly, the quantitative framework supplied by this study offers a novel tool for revisiting psychiatric classification systems with genetic clarity, moving beyond phenotypic symptom clusters toward genetically informed diagnoses.
Dr. Kendler aptly sums up the transformative nature of this work: “For over a century, we have debated whether psychiatric disorders are distinct biological entities or overlapping spectra. Now, for the first time, we can assign concrete numbers to these questions—some disorders cleave the genetic landscape clearly, while others blend extensively. Our findings compel clinicians and researchers to gauge diagnostic categories not just by symptoms but by their underlying genetic specificity.”
This landmark investigation not only advances psychiatric genetics by illuminating the heterogeneous genetic constitution of mental illness, but it also exemplifies how interdisciplinary collaboration and large-scale population science can bridge molecular biology, epidemiology, clinical psychiatry, and public health. Open Access publication in Genomic Psychiatry ensures that these insights will catalyze further research, shaping the future of psychiatric nosology and precision medicine.
Subject of Research: People
Article Title: The specificity of genetic risk for psychiatric and substance use disorders: Its modification by age at onset, recurrence, and site of treatment
News Publication Date: 3-Mar-2026
Web References: https://doi.org/10.61373/gp026a.0024
Image Credits: Kenneth S. Kendler
Keywords: Genetic specificity, psychiatric genetics, schizophrenia, bipolar disorder, substance use disorder, family genetic risk scores, psychiatric classification, recurrence, age at onset, treatment setting, comorbidity, population-based study
